The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Open accessAbstract
Introduction: Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention. Methods: A global, double-blind, 6-month study of patients with episodic migraine was undertaken with 915 intent-to-treat patients randomized to monthly galcanezumab 120 mg (n = 231) or 240 mg (n = 223) or placebo (n = 461) subcutaneous injections. Primary endpoint was overall mean change from baseline in monthly migraine headache days. Key secondary endpoints were ≥50%, ≥ 75%, and 100% response rates; monthly migraine headache days with acute migraine medication use; Patient Global Impression of Severity rating; the Role Function-Restrictive score of the Migraine-Specific Quality of Life Questionnaire. Results: Mean monthly migraine headache days were reduced by 4.3 and 4.2 days by galcanezumab 120 and 240 mg, respectively, and 2.3 days by placebo. The group differences (95% CIs) versus placebo were 2.0 (−2.6, −1.5) and 1.9 (−2.4, −1.4), respectively. Both doses were superior to placebo for all key secondary endpoints. Injection site pain was the most common treatment-emergent adverse event, reported at similar rates in all treatment groups. Both galcanezumab doses had significantly more injection site reactions and injection site pruritus, and the 240 mg group had significantly more injection site erythema versus placebo. Conclusions: Galcanezumab 120 or 240 mg given once monthly was efficacious, safe, and well tolerated. Study identification: EVOLVE-2; NCT02614196; https://clinicaltrials.gov/ct2/show/NCT02614196 . Trial Registration: NCT02614196.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Goadsby, P. J., & Edvinsson, L. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,158
Cgrp May Play A Causative Role in Migraine
Lassen, L., Haderslev, P., Jacobsen, V., Iversen, H., Sperling, B., & Olesen, J. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00310.x · Cited by 1,027
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1988) · Annals of Neurology · doi:10.1002/ana.410230214 · Cited by 863
Migraine: Multiple Processes, Complex Pathophysiology
Burstein, R., Noseda, R., & Borsook, D. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0373-15.2015 · Cited by 838
Iyengar, S., Ossipov, M. H., & Johnson, K. W. (2017) · Pain · doi:10.1097/j.pain.0000000000000831 · Cited by 584
Self-citationDiamond, S., Bigal, M. E., Silberstein, S., Loder, E., Reed, M., & Lipton, R. B. (2007) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00631.x · Cited by 413
Dodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Lipton, R. B., & Silberstein, S. D. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12505_2 · Cited by 322
Current practice and future directions in the prevention and acute management of migraine
Goadsby, P. J., & Sprenger, T. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70005-3 · Cited by 230
Skljarevski, V., Oakes, T. M., Zhang, Q., Ferguson, M. B., Martinez, J., Camporeale, A., Johnson, K. W., Shan, Q., Carter, J., Schacht, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3859 · Cited by 172
Self-citationAdherence with Migraine Prophylaxis in Clinical Practice
Berger, A., Bloudek, L. M., Varon, S. F., & Oster, G. (2012) · Pain Practice · doi:10.1111/j.1533-2500.2012.00530.x · Cited by 118
Migraine: The seventh disabler
Steiner, T., Stovner, L., & Birbeck, G. (2013) · Cephalalgia · doi:10.1177/0333102412473843 · Cited by 117
Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical Considerations
Loder, E., & Rizzoli, P. B. (2011) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.01986.x · Cited by 36
Peck, K. R., Johnson, Y. L., & Smitherman, T. A. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00016-1 · Cited by 26
Cited by
Ashina, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1915327 · Cited by 816
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018) · Neurology · doi:10.1212/wnl.0000000000006640 · Cited by 563
CGRP and the Trigeminal System in Migraine
Iyengar, S., Johnson, K. W., Ossipov, M. H., & Aurora, S. K. (2019) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13529 · Cited by 486
Self-citationSacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Ashina, M., Saper, J., Cady, R., Schaeffler, B. A., Biondi, D. M., Hirman, J., Pederson, S., Allan, B., & Smith, J. (2020) · Cephalalgia · doi:10.1177/0333102420905132 · Cited by 380
Metadata
- Authors
- Skljarevski, V., Matharu, M., Millen, B. A., Ossipov, M. H., Kim, B.-K., & Yang, J. Y.
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2018-05-31
- Volume
- 38
- Issue
- 8
- Pages
- 1442-1454
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- OpenAlex
- W2805181790
- Cited by
- 531
- References
- 20
- FWCI
- 42.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.